The study, led by Kaiyuan Cen of Guidong People’s Hospital of Guangxi Zhuang Autonomous Region and Zhuoqiao He of the First Affiliated Hospital of Shantou University Medical College, was a single-centre retrospective cohort study of adults hospitalized with chronic heart failure between 31 May 2023 and 31 May 2024, with follow-up data locked on 31 May 2025. Of 201 patients screened, 160 met the inclusion criteria, and the clinical stakes of the exercise were immediately apparent: 68 of those 160 patients—42.5 per cent—experienced a major adverse cardiovascular event, or MACE, within a year of their index hospitalization. That figure underscores a persistent problem in cardiology. Chronic heart failure remains a condition of high and unevenly distributed risk, and the field has long lacked tools that can reliably separate the patient who will be readmitted or die within months from the one who will remain stable on guideline-directed therapy.

The technical core of the new approach lies in the transformation of the conventional 12-lead ECG into a vectorcardiogram using the Kors method, a well-established mathematical technique that reconstructs the heart’s electrical dipole as a rotating vector in three-dimensional space. Rather than viewing the heart’s depolarization and repolarization through the fixed projections of twelve surface electrodes, the vectorcardiogram traces the path of the cardiac electrical axis as a loop in the frontal, horizontal, and sagittal planes. From this reconstruction, the researchers extracted features that are difficult or impossible to appreciate on a standard tracing: the spatial angles between the QRS complex, which represents ventricular depolarization, and the T wave, which represents repolarization. Discordance between these two processes—measured as a wide QRS–T angle in any plane—is thought to reflect abnormal ventricular conduction and repolarization heterogeneity, electrophysiological substrate that has been linked in prior studies to arrhythmic death and adverse remodelling.

The prespecified primary model was deliberately parsimonious, incorporating just six predictors: left ventricular end-diastolic diameter (LVEDD) measured by echocardiography, New York Heart Association functional class, the frontal, horizontal, and sagittal QRS–T angles, and a binary morphological feature known as the QRS-loop reversal/U-turn sign. The latter is a qualitative abnormality in which the ventricular depolarization loop reverses its direction of rotation or executes a U-shaped turn, signalling aberrant conduction pathways. Notably, the investigators evaluated whether two of the most celebrated markers in heart failure prognostication—brain natriuretic peptide (BNP) and left ventricular ejection fraction (LVEF)—added value beyond the six-predictor set, embedding them in full-model, comparator-model, and incremental-value analyses. Because the prediction target was a fixed 12-month probability rather than a time-to-event hazard, the team used multivariable logistic regression as the primary modelling framework, an appropriate choice for a binary endpoint observed over a uniform window.

The performance figures reported in the paper are striking. The six-predictor model produced an apparent AUC of 0.946, with a 95 per cent confidence interval of 0.914 to 0.978. Recognizing that apparent performance on the development dataset invariably overstates true predictive ability, the researchers subjected the model to bootstrap internal validation using 1,000 resamples. This procedure yielded an AUC optimism estimate of just 0.012, leaving an optimism-corrected AUC of 0.934. Calibration was assessed with equal rigour: the apparent Brier score of 0.091 rose modestly to 0.106 after bootstrap correction, calibration-in-the-large was −0.009, and the calibration slope was corrected from a perfect 1.000 to 0.852, with the same uniform shrinkage factor applied to the model’s coefficients to guard against overfitting in future applications. A shrinking factor of 0.852 means each predictor’s coefficient is tempered by roughly fifteen per cent, a standard penalty that trades a small loss in apparent fit for improved generalizability.

Perhaps the most clinically persuasive result came from the incremental-value analyses. When the VCG-derived features were added to a conventional base model built on standard clinical predictors, the AUC rose from 0.890 to 0.955—a difference of 0.065 that reached statistical significance at DeLong P = 0.001. The augmented model also achieved a lower Brier score and favourable discrimination and reclassification indices, indicating that it did not merely rank patients differently but genuinely moved them into more accurate risk categories. Decision-curve analysis, a method that evaluates the net clinical benefit of a model across a range of risk thresholds, suggested that the VCG-augmented approach would deliver higher net benefit than selected single-marker comparators within the development cohort. In practical terms, this means that at most clinically meaningful threshold probabilities, acting on the model’s predictions would identify more true events and generate fewer false alarms than relying on any single conventional marker alone.

The biological rationale for why these VCG features carry such prognostic weight is grounded in decades of electrophysiological research. Prior work has demonstrated that a wide spatial QRS–T angle predicts cardiac death in the general population, that the frontal QRS–T angle predicts increased morbidity and mortality in chronic heart failure, and that vectorcardiographic findings are associated with recurrent ventricular arrhythmias in patients with implantable cardioverter-defibrillators. The QRS–T angle quantifies the degree of spatial discordance between the sequence of ventricular activation and the sequence of recovery—discordance that widens as conduction disease, ischaemia, and structural remodelling accumulate in the failing myocardium. The QRS-loop reversal/U-turn sign adds morphological information about the activation pathway itself, capturing abnormalities such as conduction delay and scar-related altered depolarization that angle measures alone may miss. Together with echocardiographic ventricular dimensions and symptomatic status, these features sketch a compact portrait of both the structure and the electrophysiology of the failing heart.

The authors are careful, appropriately so, to frame the work as a development and internal validation study rather than a demonstration of clinical readiness. Internal validation by bootstrap quantifies how much a model’s apparent performance is inflated by overfitting to its own data, but it cannot address the questions that matter most before deployment: whether the model generalizes to patients from different hospitals, ethnic backgrounds, and health systems; whether ECG acquisition and processing pipelines elsewhere would yield comparable VCG reconstructions; and whether clinicians acting on the model’s outputs would genuinely alter management in ways that improve outcomes. The de-identified analytic dataset cannot be made publicly available owing to institutional privacy requirements, though statistical code and data excerpts are available from the corresponding author on reasonable request. The study received no external funding, was approved by the Ethics Committee of Guidong People’s Hospital under approval number GDKY202590, and the authors declare no competing interests.

Even so, the appeal of the approach is hard to overstate. It requires no new hardware, no additional blood draws, and no expensive imaging: the raw material is a routine ECG already recorded for virtually every hospitalized heart failure patient, and the transformation to a vectorcardiogram is a computational step that can be automated in seconds. In an era when deep learning models have shown that ECG voltage data alone can predict mortality, the present work occupies a complementary middle ground—using interpretable, physiologically grounded features extracted from the same inexpensive signal, within a transparent logistic regression framework whose coefficients clinicians can inspect rather than a black box they must trust blindly. Each of the six predictors maps onto a familiar clinical concept: ventricular size, symptom severity, ventricular conduction, and repolarization geometry.

The study team, which also included Hong Chen of the University of Tsukuba, Yi Tan of Guidong People’s Hospital, Lixia Lin of Guangxi University of Chinese Medicine, and Xiaojuan Xu of Tongji University, emphasizes that external multicentre validation is required before any clinical implementation. That caveat is the correct one, and it sets the agenda for the next stage of this line of research. If the 0.934 optimism-corrected AUC survives contact with independent cohorts, heart failure teams could gain a near-zero-cost decision support tool for flagging the roughly four in ten hospitalized patients who face a major cardiovascular event within a year—enabling intensified follow-up, earlier escalation of therapy, and closer surveillance of the patients whose electrical signatures betray a heart in the greatest danger.

Historically, sudden cardiac death has been characterized by its abrupt onset, often occurring without prior warning signs or critical deterioration. However, the current analysis challenges this paradigm by demonstrating that patients destined to experience sudden death frequently manifest subtle but measurable clinical worsening. Notably, symptoms intensify modestly, patients’ quality of life deteriorates, and levels of circulating natriuretic peptides—biochemical markers of cardiac stress—increase in the weeks leading up to the fatal event. These markers have long been implicated in heart failure pathophysiology, serving as valuable tools for both diagnosis and prognosis.

The FINEARTS-HF trial cohort, drawn from contemporary clinical populations with HFmrEF and HFpEF, provides an ideal substrate for investigating sudden death dynamics. These groups have historically been underrepresented in heart failure research, which has predominantly focused on those with reduced ejection fraction (HFrEF). Given the distinct pathophysiological mechanisms and less clearly defined treatment protocols for HFmrEF and HFpEF, understanding the precursors to sudden death within this demographic addresses a critical unmet need in cardiovascular medicine.

Using a battery of rigorous longitudinal assessments, researchers quantified patient-reported symptom severity alongside objective biomarker profiles. This dual approach enabled them to correlate subjective clinical experiences with measurable biochemical evidence of cardiac strain. Importantly, rising natriuretic peptide levels emerged as a consistent harbinger of imminent mortality risk, corroborating prior studies yet adding granularity regarding timing and severity. The gradual deterioration challenges the notion that sudden death is purely an unheralded event and instead suggests a window of opportunity for intervention.

Intriguingly, the study also reports that similar pre-mortem clinical deterioration occurred in patients who succumbed to other modes of death, such as progressive heart failure or non-cardiovascular causes. This observation highlights the complexity of differentiating sudden cardiac death from other fatal trajectories based solely on symptomatology and biomarkers. Therefore, although the patterns of worsening offer important clues, their specificity for sudden death events remains limited, underscoring the necessity for more refined predictive models.

Clinicians managing patients with HFmrEF and HFpEF may need to rethink risk stratification frameworks in light of these findings. Continuous monitoring of natriuretic peptide trends and symptom burden could provide valuable real-time data to identify those at risk for fatal arrhythmias or cardiac arrest. This approach contrasts with current strategies that rely heavily on static measures like ejection fraction or historical events. Personalized surveillance protocols incorporating dynamic biomarker changes could revolutionize care by enabling anticipatory interventions.

Mechanistically, the findings invite deeper exploration into the pathophysiological cascade underpinning sudden death in heart failure populations with preserved or mildly reduced ejection fractions. Unlike HFrEF, where ventricular remodeling and systolic dysfunction have been extensively characterized, HFpEF and HFmrEF involve complex diastolic abnormalities, microvascular dysfunction, and systemic inflammation. The progressive rise in natriuretic peptides might reflect increasing myocardial wall stress, fluid overload, or neurohormonal activation that collectively destabilize cardiac electrophysiology, precipitating lethal arrhythmias.

Future research trajectories may focus on integrating advanced imaging modalities, electrophysiological monitoring, and biomarkers to build comprehensive risk profiles before sudden death occurs. Additionally, the modest symptom worsening documented prior to fatal events suggests that leveraging patient-reported outcomes combined with wearable technologies could empower patients and providers alike. By capturing early signals of decompensation, clinicians may deploy tailored therapies such as device implantation or pharmacological modulation to avert catastrophic outcomes.

These revelations emerge in the broader context of evolving paradigms about heart failure phenotypes and their mortality risks. With the American College of Cardiology spotlighting these results at its 75th Annual Scientific Session & Expo, the clinical community is poised to engage in robust debate over redefining sudden death definitions and prevention tactics. Incorporating these insights into guidelines could enhance survival in a population historically challenged by therapeutic limitations and diagnostic uncertainties.

In sum, the FINEARTS-HF post hoc analysis elucidates a critical dimension of sudden death in contemporary heart failure populations that warrants urgent clinical and scientific attention. By mapping the subtle yet discernible clinical and biochemical deterioration preceding fatal events, this study paves the way toward more effective risk identification and preemptive care strategies. As the understanding of heart failure pathophysiology deepens, so too does the potential to transform sudden death from a feared inevitability to a preventable endpoint.

The work was led by corresponding author Dr. Scott D. Solomon at Brigham and Women’s Hospital, whose pioneering efforts continue to advance the field of cardiovascular therapeutics. The full study is available in JAMA Cardiology and offers extensive data on symptom trajectories, biomarker kinetics, and methodological rigor in assessing sudden death phenomena. Importantly, while the study clarifies many aspects of mortality patterns, it also leaves fertile ground for future inquiry into the mechanisms that differentiate sudden death from other lethal heart failure outcomes.

These findings compel a reexamination of patient monitoring frameworks, clinical decision-making, and therapeutic approaches in HFmrEF and HFpEF. Embracing a dynamic view of disease progression rather than static risk assessments aligns with the broader movement toward precision medicine in cardiology. Ultimately, the integration of these novel insights may reduce sudden death incidence, improve quality of life, and extend survival in this vulnerable patient population, marking a significant milestone in heart failure management.

Subject of Research: Sudden death and preceding clinical deterioration in heart failure with mildly reduced or preserved ejection fraction.

Article Title: Not specified in provided content.

News Publication Date: Not specified in provided content.

Web References: doi:10.1001/jamacardio.2026.0682

References: See original JAMA Cardiology article.

Image Credits: Not specified in provided content.

Keywords: Heart failure, HFmrEF, HFpEF, sudden death, natriuretic peptides, clinical deterioration, biomarkers, cardiovascular mortality, FINEARTS-HF trial, risk stratification, cardiology, arrhythmia prevention.